Article

Effect of Pharmacological Treatment of Depression on A1C and Quality of Life in Low-Income Hispanics and African Americans With Diabetes

Charles Drew University, Los Angeles, California, USA.
Diabetes care (Impact Factor: 8.57). 09/2009; 32(12):2156-60. DOI: 10.2337/dc09-0785
Source: PubMed

ABSTRACT To determine whether pharmacological treatment of depression in low-income minorities with diabetes improves A1C and quality of life (QOL).
This was a 6-month, randomized, double-blind, placebo-controlled trial. Patients were screened for depression using Whooley's two-question tool at a county diabetes clinic. Depression was confirmed (or not) with the Computerized Diagnostic Interview Survey (CDIS) software program, and the severity of depression was assessed monthly by the Hamilton Depression Scale (HAM-D). Depressed subjects with A1C levels >or=8.0% were randomly assigned to receive either sertraline or placebo. Diabetes care was provided by nurses following detailed treatment algorithms who were unaware of therapy for depression.
A total of 150 subjects answered positively to at least one question on Whooley's questionnaire. The positive predictive value for depression diagnosed by CDIS was 69, 67, and 84% for positive answers to question 1 only, question 2 only, or both, respectively. Of the 89 subjects who entered the study, 75 completed. An intention-to-treat analysis revealed significant differences between baseline and 6 months in HAM-D and pain scores, QOL, and A1C and systolic blood pressure levels in both groups, with no differences between groups for the first three but a significantly greater decrease with sertraline in A1C and systolic blood pressure levels. Changes in HAM-D scores and A1C levels were significantly correlated in all subjects (P = 0.45 [P < 10(-6)]).
In this low-income minority population, pharmacological treatment of depression significantly improved A1C and systolic blood pressure levels compared with placebo.

Download full-text

Full-text

Available from: Diana Echeverry, Sep 12, 2014
0 Followers
 · 
111 Views
  • Source
    • "Interestingly, among the SSRIs, sertraline and escitalopram are preferable since they have a slight inhibitory effect on cytochrome P-450 isoenzymes 3A4 and 2D6, responsible by metabolism of many drugs used to treat diabetes and/or other comorbidity associated [246] [247] [239]. Conversely, fluoxetine inhibits the cytochrome P-450 isoenzymes complex [248] requiring adjustment of the dose of hypoglycemic agents, in particular insulin [226]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes is a chronic and progressive syndrome commonly associated with several neuropsychiatric comorbities, of which depression is the most studied. The prevalence of depression is about two or three times higher in diabetic patients compared to the general population. It is believed that the diabetes - depression relation may be bidirectional, i.e., the depression can lead to diabetes and conversely diabetes could facilitate the emergence of depression. Depression is one of the most neglected symptoms in diabetic patients and is directly linked with lowering of quality of life. The treatment of depression in these patients is still quite ineffective and in many cases treatment-refractory. Furthermore, some of the first choice drugs used to treat the depression affect the blood glucose control, aggravating the hyperglycemic state. These issues underscore the urgency in studies searching for new pharmacological targets for the treatment of depression associated with diabetes. For this, a better understanding of the pathophysiology that relates this comorbidity becomes critical. In this respect, this review will focus on some hypotheses that have been proposed to explain the mechanisms underlying depression associated with diabetes, highlighting the treatment options currently available and their limitations. Among these hypotheses, we will point out the hyperglycemia as a primary metabolic cause of the depression development, the involvement of the dysregulation of hypothalamic pituitary-adrenal (HPA) axis and of neurotransmitter systems, specially monoaminergic system. Besides, the role of oxidative stress, neuroinflammation and cell death, especially in hippocampus and prefrontal cortex, brain areas important for the mediation and modulation of emotional behavior will also be discussed. Finally, we will bring up the influence of the epigenetic regulation with respect to neuropsychiatric disorders.
    Current diabetes reviews 05/2015;
  • Source
    • "In a previous study, the sertraline effect was shown to be no better than the usual more active care delivered by the same health-care practitioner (Echeverry et al., 2009). Only by carrying out a controlled trial against the absence of any specific treatment, with several therapists and patient motivation level taking into account, can these kinds of doubts be clarified. "
    [Show abstract] [Hide abstract]
    ABSTRACT: AIMS: Major depression is more prevalent in patients with type 2 diabetes mellitus (T2DM) than in general population. Comparing psychotherapeutic and pharmacological treatment responses could help to inform the choice between available treatment options. METHOD: Thirty-four patients with T2DM and major depression detected by using the Hospital Anxiety-Depression Scale (HADS), the Montgomery-Äsberg Depression Rating Scale (MADRS) and a structured interview (Mini-International Neuropsychiatric Interview) were randomized to undergo Interpersonal Psychotherapy (IPT) or treatment with sertraline in a 3-month acute intervention course in addition to a 3-month continuation format. Provided that the initial MADRS score was not reduced ≥25% at week 6, these early non-responding patients continued treatment in a sequential add-on combined format. Psychological adjustment to diabetes, attachment style, diabetes self-efficacy, quality of life and HbA1c were also evaluated along intervention. RESULTS: Out of 22 early-responding patients (11 for each treatment type), 16 had clinically significant improvements (<50% initial MADRS score) at endpoint with 11 reaching remission (MADRS scores ≤8), and with no significant differences between IPT and sertraline. Within sequential add-on treatment, out of eight patients, only three of them achieved a clinically significant improvement and only one reached remission. CONCLUSIONS: These preliminary results suggested that IPT may be an option to treat major depression in T2DM against medical care with sertraline. Early non-responding patients likely need alternative or longer treatment interventions. Limitations of this study relate to small sample and absence of a control group, which was difficult to implement due to ethical restrictions. Copyright © 2012 John Wiley & Sons, Ltd. KEY PRACTITIONER MESSAGE: Findings suggest that Interpersonal Psychotherapy is a useful tool to treat major depression in type 2 diabetes patients. A significant number of type 2 diabetes patients with major depression do not achieve depression remission irrespective of the type of treatment. Further clinical research should focus on addictive effects of psychotherapy and psychopharmacology in the treatment of depressed patients with chronic somatic diseases.
    Clinical Psychology & Psychotherapy 01/2014; 21(1). DOI:10.1002/cpp.1817 · 2.59 Impact Factor
  • Source
    • "Fluoxetine and paroxetine have been compared in a single trial, and were both equally effective [64]. Whilst a couple of studies have reported trends to improved glycemic control with fluoxetine [61] [64], only one trial of sertraline was found to significantly improve glycemic control relative to the placebo group after 6 months of treatment [67]. In this study, baseline HbA1c improved from 10.0% to 8.0% in the sertraline treated group versus 9.7% to 8.8% in the placebo group (p < 0.01). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Family physicians are responsible for diagnosing and treating the majority of people with type 2 diabetes mellitus and co-morbid depression. As a result of the impact of co-morbid depression on patient self-care and treatment outcomes, screening for depression in the context of a structured approach to case management and patient follow up is recommended in people with diabetes and cardiovascular disease. This review summarizes the need for improved recognition and treatment of depression in diabetes; and makes expert recommendations with regard to integrating screening tools and therapies into a busy family or general medical practice setting.
    Primary Care Diabetes 12/2012; 7(1). DOI:10.1016/j.pcd.2012.11.002 · 1.29 Impact Factor
Show more